Quest diagnostics inc(DGX.US AI Earnings Summary)
DGX AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
Net revenue grew 10% year-over-year this quarter, and the full-year EPS guidance was raised; strong hospital and consumer channels drove performance growth.
- Market Expectations: No market consensus data available for comparison.
- Previous Quarter Guidance: All targets met; full-year revenue and EPS guidance were upgraded.
- In One Sentence: QUEST DIAGNOSTICS INC achieved impressive revenue and profit performance this quarter, driven by double-digit growth in hospital Co-Lab Solutions and consumer health channels, leading to another upward revision of full-year expectations.
Quarterly Highlights
The simultaneous acceleration of three channels and the record-high organic growth momentum in recent years are the most noteworthy structural signals this quarter.
Comprehensive Top-line Strength: Consolidated revenue this quarter was $3.1 billion, up 10.0% year-over-year; Diagnostic Information Services revenue was $3.035 billion, up 10.2%, with organic growth of 10.1%. Adjusted diluted earnings per share (Non-GAAP) was $3.00, a 15.4% increase compared to $2.60 in the same period last year, significantly outpacing revenue growth and demonstrating continued operating leverage.
Accelerated Organic Volume; 5% Base Growth Excluding Large Partnerships: Total test requisition volume increased 14.5% year-over-year, with organic volume up 14.4%. The two major partnerships with Corewell Health and Fresenius Medical Care contributed 9.5 percentage points. Excluding these two relationships, base volume growth still reached 5%, corresponding to organic revenue growth of 6.6%, reflecting broad demand across physician, hospital, and consumer channels.
High-Single-Digit Growth in Physician Channel, Double-Digit Growth in Hospital Channel: Revenue in the physician channel grew by high single digits this quarter, driven by strong commercial execution and broad demand for test portfolios. The hospital channel (including Corewell Co-Lab solutions) achieved double-digit growth overall, while hospital Reference Testing revenue (testing outsourced by hospitals to Quest) grew by mid-single digits, indicating an increasing willingness of hospitals to outsource.
Consumer Health Channel Full-Year Growth Expected to Exceed 30%: CEO Jim Davis noted that the consumer health business across questhealth.com and various partner platforms is expected to grow by more than 30% for the full year. CFO Sam Samad added that the gross margin of the consumer business is higher than the company's overall operating margin due to the absence of insurance denials and patient fee concessions, with each requisition containing an average of over 10 tests, representing a high-density, high-margin business structure.
Adjusted Operating Margin Increased 40 Basis Points to 16.7%: Adjusted (Non-GAAP) operating income was $517 million, with a margin of 16.7%, up 40 basis points from 16.3% in the same period last year and up 20 basis points from 16.5% last quarter (2026 Q2). The improvement primarily came from fixed cost leverage driven by organic volume growth and the Invigorate cost-saving program, which offset a 3%~4% annual wage increase (at least $120 million in annual pressure) and rising fuel costs (expected to be about $14 million for the year).
Full-Year Outlook Raised Again, Guidance Range Narrowed: Full-year revenue guidance was raised to $12.065 billion–$12.105 billion (up 9.3%~9.7%), higher than the $11.95 billion–$12.05 billion expected last quarter. Adjusted EPS guidance was raised to $11.25–$11.35, up from the $11.05–$11.25 previously expected. Full-year operating cash flow guidance was also raised from approximately $1.8 billion to approximately $1.9 billion.
Apple Health Partnership Officially Announced; Consumer Health Ecosystem Expands: Quest announced that iPhone and iPad users can now purchase, schedule, and receive results for over 50 biomarkers (including cardiovascular indicators like ApoB and Lp(a)) directly through the Apple Health app, priced at $119, with simultaneous measurement of blood pressure and weight. CEO Jim Davis stated that the combination of biomarkers and biometric data will unlock deeper health insights, with an official launch expected by the end of the year.
Alzheimer's Test Portfolio Continues to Expand; Advanced Diagnostics Sees Double-Digit Growth: This quarter, cardiovascular metabolic, hormone, and Alzheimer's-related testing all achieved double-digit growth. Quest announced the inclusion of the FDA-approved Roche p-tau217 blood test into the AD-Detect portfolio and launched a multi-biomarker panel combining APOE, amyloid beta, and p-tau217 to improve early diagnosis accuracy.